FOLH1 and prostate adenocarcinoma: While this may create diagnostic uncertainty, it could also open therapeutic opportunities.<h4>Clinical case</h4>Here we describe a case in which a PET/CT performed to restage a patient with prostate adenocarcinoma experiencing biochemical recurrence revealed the coexistence of a PDAC.<h4>Literature review</h4>A literature review aimed to summarize the bibliographic evidence on the use of this technique in this setting, which is relatively uncommon.<h4>Conclusion</h4>Prostate-specific membrane antigen can be overexpressed in PDACs.